ViCentra Launches Smartphone-Controlled Hybrid Closed-Loop Insulin System in Germany and the Netherlands

New updates have been reported about ViCentra.

ViCentra has begun commercializing its new smartphone-controlled hybrid closed-loop insulin delivery system, built around the Kaleido insulin patch pump, with first rollouts planned in Germany and the Netherlands later this summer. The system integrates Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7 continuous glucose monitoring, positioning ViCentra to deepen its presence in key European diabetes technology markets and accelerate recurring revenue from device and consumable sales.

The company is shifting from a pilot deployment in the Netherlands to full commercial execution, and will formally introduce the commercial version at the 60th DDG Diabetes Congress in Berlin as it targets broader adoption among healthcare professionals and payers. ViCentra is also using the existing Kaleido platform with Diabeloop’s DBLG1 algorithm as an onboarding pathway, enabling patients to start on Kaleido now and transition to the DBLG2 and Dexcom G7-enabled system once it becomes available, which should smooth uptake and reduce conversion friction.

Over the past year, ViCentra has expanded commercial operations in Germany and the Netherlands and bolstered its operational readiness, laying the groundwork for scaling its differentiated automated insulin delivery platform across Europe and into the U.S. market. The new system’s smartphone control and smaller, all-in-one Dexcom G7 sensor are designed to make hybrid closed-loop therapy more convenient and discreet, supporting ViCentra’s strategy of competing on usability and design while maintaining clinical performance.

Chief executive Tom Arnold framed the launch as a key milestone in ViCentra’s growth plan, emphasizing that combining Kaleido, DBLG2 and Dexcom G7 is intended to simplify automated insulin delivery and better fit everyday life for people with diabetes. The company plans to provide additional details on product availability, transition pathways for existing users and market rollout timing as the summer deliveries approach, and will use its presence at the DDG Congress to engage clinicians, partners and other stakeholders who are critical to reimbursement access and long-term adoption.